<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586193</url>
  </required_header>
  <id_info>
    <org_study_id>SHIRB2018014</org_study_id>
    <nct_id>NCT03586193</nct_id>
  </id_info>
  <brief_title>Pars Plana Vitrectomy Alone in the Treatment of Macular Schisis in High Myopic Eyes</brief_title>
  <official_title>Application of Pars Plana Vitrectomy in the Treatment of Macular Schisis in High Myopic Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High myopic schisis (HMF) has the clinical feature of separation between retinal layers. It
      is sometimes accompanied with foveal retinal detachment, macular lamellar hole, epiretinal
      membrane and vitreous retraction. HMF may develop to macular hole, macular detachment and
      will damage the visual function. Pars plana vitrectomy (PPV) is a commonly used surgery in
      the treatment of HMF. PPV together with internal limiting membrane (ILM) peeling and
      long-term gas tamponade was reported to be safe and effective. But nowadays there was no
      available long-term gas in our country. Also, whether ILM peeling is necessary remains
      controversial, Indole cyanine green (ICG)was proved to have potential toxicity to the retina
      and the ILM peeling has the risk of causing secondary macular hole. We propose to make a
      prospective nonrandomized controlled study to evaluate the safety and efficiency of using PPV
      alone in the treatment of HMF.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The morphologic change of macular area</measure>
    <time_frame>OCT will be done one day before surgery and one week, one month, three months and six months after surgery</time_frame>
    <description>The thickness of the macular fovea in optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The best corrected visual acuity (BCVA) change</measure>
    <time_frame>One day before surgery and one week, one month, three months and six months after surgery</time_frame>
    <description>The BCVA of all involved patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The best corrected near visual acuity (BCNVA) change</measure>
    <time_frame>One day before surgery and one week, one month, three months and six months after surgery</time_frame>
    <description>The BCNVA of all involved patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The visual function change</measure>
    <time_frame>One day before surgery and one week, one month, three months and six months after surgery</time_frame>
    <description>The contrast sensitivity of all involved patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Retinal Disease</condition>
  <condition>Macular Retinoschisis</condition>
  <arm_group>
    <arm_group_label>patients with HMF</arm_group_label>
    <description>Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy</intervention_name>
    <description>pars plana vitrectomy without ICG staining and ILM peeling</description>
    <arm_group_label>patients with HMF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will be selected from the in-patients in Shanghai Aier Eye Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed as high myopic macular retinoschisis, with axial length more than
             26.5mm.

          2. Morphologic manifestation in OCT shows split between retinal layers in macular area.

          3. Patients without severe systemic disease and can tolerate surgery.

        Exclusion Criteria:

          1. Patients also have other ocular disease, including glaucoma, keratitis,uveitis,
             retinal detachment,etc.

          2. Patients with nystagmus or have difficult to open the eye.

          3. Patients with severe systemic disease and cannot tolerate surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wensheng Li, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Aier Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuyun Qian, Doctor</last_name>
    <phone>+8613817109809</phone>
    <phone_ext>+8618650424985</phone_ext>
    <email>qianzhuyun552@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wensheng Li, Doctor</last_name>
    <phone>+8618650424985</phone>
    <phone_ext>+8618650424985</phone_ext>
    <email>drlws@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Aier Eye hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuyun Qian, Doctor</last_name>
      <phone>+8613817109809</phone>
      <phone_ext>+8618650424985</phone_ext>
      <email>qianzhuyun552@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Wensheng Li, Doctor</last_name>
      <phone>+8618650424985</phone>
      <phone_ext>+8618650424985</phone_ext>
      <email>drlws@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chang JS, Flynn HW Jr, Engelbert M, Shane AR, Smiddy WE, Chang S. Pars plana vitrectomy in patients with myopic macular retinoschisis. Br J Ophthalmol. 2014 Apr;98(4):534-7. doi: 10.1136/bjophthalmol-2013-304578. Epub 2014 Jan 10.</citation>
    <PMID>24414402</PMID>
  </reference>
  <results_reference>
    <citation>Zhang Z, Wei Y, Jiang X, Zhang S. PARS PLANA VITRECTOMY AND WIDE INTERNAL LIMITING MEMBRANE PEELING WITH PERFLUOROPROPANE TAMPONADE FOR HIGHLY MYOPIC FOVEOSCHISIS-ASSOCIATED MACULAR HOLE. Retina. 2017 Feb;37(2):274-282. doi: 10.1097/IAE.0000000000001146.</citation>
    <PMID>27429390</PMID>
  </results_reference>
  <results_reference>
    <citation>Rey A, JÃ¼rgens I, Maseras X, Carbajal M. Natural course and surgical management of high myopic foveoschisis. Ophthalmologica. 2014;231(1):45-50. doi: 10.1159/000355324. Epub 2013 Nov 12.</citation>
    <PMID>24246446</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinoschisis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all individual participant data (IPD) that underlie results</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After this study is finished the data will become available for 1year.</ipd_time_frame>
    <ipd_access_criteria>The analytical data will be accessed in published articles.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

